Bone conduction devices (BCDs) are an established form of treatment for conductive hearing loss or single-sided sensorineural deafness (SSD). The BCDs work by converting sound energy to vibration of the skull bones, which results in a wave in the basilar membrane of the cochlea similar to that produced through air conduction of sound.
1 It is well known that BCDs improve hearing outcomes in patients with SSD, via the principle of rerouting sound from the affected side of the head to the contralateral normally hearing ear.
2-4 To our knowledge, the effects of BCDs on quality of life (QOL) have been less well evaluated. Studies have explored individual nonhearing benefits of BCDs in SSD without demonstrating improvement.
5 In literature reviews evaluating the association of BCDs with overall QOL in patients with unilateral and bilateral hearing loss,
2,6 many studies are underpowered or show only modest benefits (reporting safety and “satisfaction”), meaning it remains unclear from these publications whether patients with SSD experience a meaningful QOL benefit.